Recent developments include the Q4 2025 earnings call, a product launch of the HydraGuard 20” UltraFilter, and ongoing financial reporting and governance updates.

• Nephros held its Q4 2025 earnings call, discussing financial results and operational updates [N1].
• The company launched the HydraGuard 20” UltraFilter product in October 2024, expanding its filtration product line [N3].
• Nephros reported net income for the fiscal year 2025, with EPS of $0.11 and strong liquidity ratios as of December 31, 2025 [S1].
• The Board approved an increase in CEO Robert Banks' base salary to $400,000 effective October 1, 2025, reflecting company performance [S2].

Nephros benefits from proprietary ultrafiltration technology and exclusive licensing agreements that support product differentiation. The launch of new products like the HydraGuard 20” UltraFilter demonstrates ongoing innovation. The company reported net income and positive EPS in 2025, supported by strong liquidity ratios, indicating operational progress. Experienced leadership and a focused governance structure provide a foundation for strategic execution. These factors collectively support the visibility of Nephros' business model and potential for operational improvements [S1][S2][N1][N3].

Nephros faces risks from reliance on third-party contractors for installation and servicing, which could lead to product performance issues, warranty claims, and reputational damage if not managed effectively. The company has disclosed a material weakness in internal controls over financial reporting related to revenue recognition, which could affect financial reporting reliability if not remediated. Additionally, exposure to tariff policies affecting imported materials could impact costs and margins. Historical periods of losses highlight operational challenges. These factors introduce uncertainty and risks to the company's business execution and financial stability [S2][N4].

Nephros' moat is based on its proprietary ultrafiltration technology and exclusive licensing agreements, such as with Medica S.p.A., which provide a competitive edge in water filtration products. The company's specialized filtration materials and technology, combined with its established supply arrangements, create barriers to entry. Additionally, its focus on regulatory compliance and product performance, supported by third-party installation and servicing networks, contributes to its market position. However, reliance on third-party contractors introduces operational risks that could impact reputation and customer satisfaction, which are critical to maintaining its competitive advantage [S1][S2].

• Reliance on Third-Party Contractors: Nephros depends on third-party contractors for installation and servicing of its water filtration products. Failures in performance or compliance by these contractors could harm product functionality, customer satisfaction, and the company's reputation, potentially leading to warranty claims and financial costs [S2].
• Material Weakness in Internal Controls: The company identified a material weakness in internal control over financial reporting related to revenue recognition from service-based sales contracts. Failure to remediate this weakness could affect the accuracy and timeliness of financial reporting and investor confidence [S2].
• Tariff and Trade Policy Risks: Changes in U.S. tariff policies and trade tensions could increase costs of imported materials from suppliers in the European Union, impacting Nephros' cost structure and profitability [S2].

• Nephros Inc. is a Delaware corporation headquartered in South Orange, New Jersey, engaged in water filtration products and technology [S1].
• The company markets and sells filtration products based on proprietary ultrafiltration technology, including a license and supply agreement with Medica S.p.A. for Medisulfone ultrafiltration technology, effective through 2030 with minimum annual purchase commitments [S1].
• Nephros relies on third-party contractors for installation and servicing of its water filtration products, which is critical to product performance and regulatory compliance; failures in this area could harm reputation and result in warranty claims [S2].
• The company identified a material weakness in internal control over financial reporting related to revenue recognition from service-based sales contracts and is implementing remediation measures [S2].
• As of December 31, 2025, Nephros reported cash and cash equivalents of $5.4 million, current assets of $11.2 million, current liabilities of $2.77 million, resulting in a current ratio of 4.06 and a cash ratio of 1.95, indicating liquidity strength [S1].
• For the fiscal year ended December 31, 2025, Nephros reported net income of $1.19 million and basic and diluted EPS of $0.11 per share [S1].
• The company’s CEO is Robert Banks, appointed in May 2023, with a base salary increased to $400,000 effective October 1, 2025, and eligibility for performance bonuses [S1,S2].
• The Board of Directors includes members with extensive experience in finance, operations, sales, and medical device sectors, with an Audit Committee chaired by Oliver Spandow, an audit committee financial expert [S1].
• Nephros launched the HydraGuard 20” UltraFilter product in October 2024, expanding its filtration product offerings [N3].
• Recent earnings calls and financial results have been publicly discussed, including the Q4 2025 earnings call transcript [N1].
• The company has experienced periods of losses in prior years but reported a net income in 2025, reflecting operational developments [N4,N6,N7,N8].